bimagrumab tirzepatide Lilly Cuts Mid-Stage Obesity Study of Muscle-Sparing Antibody Pharmacologic Disruption: How Emerging Weight

Semaglutide requires 48 weeks to reach steady-state levels and maintains consistent weight loss benefit over months when dosed appropriately, without the same tolerance mechanism

Last reviewed: April 21, 2026 Updated with Phase 3 TRIUMPH-4 data Primary sources: NEJM, Eli Lilly, ClinicalTrials.gov Retatrutide is a triple agonist (GLP-1 + GIP + glucagon) currently in Phase 3 trials, showing stronger early weight loss data

Missing doses or inconsistent administration can delay therapeutic benefits and increase side effects when treatment is resumed

For the best results, doctors suggest you stick to a regular dosing schedule on the same day every week